Pharmaceutical
ChemLinkedMarketChemicalFoodCosmeticPharmaceuticalJapanAgrochemicalSustainability
OUR SERVICE
In all critical stages in the drug life cycle, BaiPharm can provide specific recommendations and actionable solutions to clients.

Product Registration
Pharmacovigilance
Local Agency Support
Consulting and Training
WEBINARS MORE >
webinar cover Investigational New Drug (IND) Preparation for U.S. FDA Submission
[ Thursday, 26th September 2024 ]
webinar cover A Look Back at 2023: Pharmaceutical Regulatory Updates in China
[ Tuesday, 30th January 2024 ]
webinar cover Understanding Regulatory Requirements for Exporting Drugs to Cambodia, Laos, and Myanmar
[ Wednesday, 13th December 2023 ]
webinar cover Understanding Regulatory Requirements for Exporting Drugs to Indonesia and Vietnam
[ Thursday, 30th November 2023 ]
LATEST NEWS
POLICY
NRDL China
China Adds 91 Drugs to 2024 National Reimbursement Drug List (NRDL) On November 28, 2024, China's National Healthcare Security Administration (NHSA) unveiled the 2024 National Reimbursement Drug List (NRDL), with implementation scheduled to begin on January 1, 2025.
Dec 04, 2024
POLICY
Law & Regulation Volume-based Procurement China
China Launches the 10th Round of Volume-Based Drug Procurement (VBP) On November 22, 2024, the China National Joint Drug Procurement Office launched the 10th round of volume-based procurement (VBP), involving 62 drugs. Eligible suppliers must provide basic information by 12:00 PM on December 2 and submit their application dossiers by 10:00 AM on December 12.
Nov 27, 2024
REGULATION
Law & Regulation MAH Marketing Approval Drug Registration China
China Standardizes Requirements for Domestic Responsible Persons Designated by Overseas MAHs On November 14, 2024, China's National Medical Products Administration (NMPA) issued the Interim Provisions on the Management of Designated Domestic Responsible Persons by Overseas Marketing Authorization Holders (MAH) of Drugs.
Nov 19, 2024
REGULATION
Law & Regulation Marketing Approval Generic Drug Drug Registration China
Monthly Recap: China Pharmaceutical Regulatory Updates | October 2024 Check out the latest pharma regulatory updates in China: 1. China Releases Several Lists of Reference Listed Drugs (RLDs), 2. China Publishes Re-registration Requirements for Domestically Manufactured Drugs, 3. China Consults on Scope and Procedures for Bioequivalence Test Filings of Chemical Drugs, 4. China CDE Releases Dossier Requirements for the Transfer of Imported Preventive Biological Products to Domestic Production...
Nov 13, 2024
INDUSTRY
Innovative Drug Generic Drug New Drug China
Monthly Report: New Drug Approvals in China | October 2024 In October 2024, China NMPA approved 11 new drugs, among which 6 are chemical drugs and 5 are biological products.
Nov 11, 2024
INDUSTRY
Innovative Drug OTC Drug Cancer Respiratory Disease China
An Overview of Drug Sales in China In 2023, China’s pharmaceutical market saw steady growth marked by both rising drug sales and an influx of new drug applications.
Nov 06, 2024
INDUSTRY
Pharmacopoeia Cardiovascular Disease E-commerce China
China's Pharmaceutical Retail Market Value Hits RMB 245.8 Billion in 2024H1 From January to June 2024, the pharmacy retailing market value has reached RMB 245.8 billion (about USD 34.76 billion), up by 0.4% year on year.
Oct 17, 2024
INDUSTRY
Innovative Drug Generic Drug Biosimilar New Drug China
Monthly Report: New Drug Approvals in China | September 2024 In September 2024, China NMPA approved 21 new drugs, among which 14 are chemical drugs and 7 are biological products.
Oct 14, 2024
MORE >
INSIGHTS MORE >
cover Decoding China's Good Pharmacovigilance Practices (GVP)
cover 2023 China CDE Drug Evaluation Report
cover China's Drug Supply Regulations Come into Effect
adv-image adv-image adv-image